Half-Year 2022 Financial and Clinical Trials Update

Xolair Global sales CHFbn CER growth +11% Regional sales CER growth 1.2 1.0 0.8 0.6 0.4 0.2 0.0 HY 19 HY 20 HY 21 HY 22 US +11% HY 2022 sales of CHF 1,025m • US: Xolair remains market leader in growing biologics asthma market; Growth driven by chronic idiopathic urticaria (CIU) CER-Constant Exchange Rates Roche 179

View entire presentation